Ministry of Health issued registration certificate for the medicine “Tamerit”.
We are pleased to announce that on December 4, 2024 the Ministry of Health of the Russian Federation issued registration certificate LP-№(007959)-(RG-RU) for “Abidapharma” (LLC) for the medicine “Tamerit” - aminodihydrophthalazindione sodium lyophilizate for preparation of solution for intramuscular injection.
The mechanism of action of the drug is associated with its ability to regulate the functional and metabolic activity of cells of innate and adaptive immunity (monocytes, macrophages, neutrophils, natural killer cells, etc.). "Tamerit" normalizes phagocytic activity of monocytes/macrophages, bactericidal activity of neutrophils and cytotoxic activity of NK-cells. At the same time, restoring the reduced activity of cells of innate and adaptive immunity, the drug increases the body's resistance to infectious diseases.
The drug is indicated as an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency states in adults and children from 12 years of age.
We congratulate our colleagues and clients from “Abidapharma” (LLC) and wish them further success in the Russian pharmaceutical market!
We are pleased to announce that on December 4, 2024 the Ministry of Health of the Russian Federation issued registration certificate LP-№(007959)-(RG-RU) for “Abidapharma” (LLC) for the medicine “Tamerit” - aminodihydrophthalazindione sodium lyophilizate for preparation of solution for intramuscular injection.
The mechanism of action of the drug is associated with its ability to regulate the functional and metabolic activity of cells of innate and adaptive immunity (monocytes, macrophages, neutrophils, natural killer cells, etc.). "Tamerit" normalizes phagocytic activity of monocytes/macrophages, bactericidal activity of neutrophils and cytotoxic activity of NK-cells. At the same time, restoring the reduced activity of cells of innate and adaptive immunity, the drug increases the body's resistance to infectious diseases.
The drug is indicated as an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency states in adults and children from 12 years of age.
We congratulate our colleagues and clients from “Abidapharma” (LLC) and wish them further success in the Russian pharmaceutical market!